FDA 510(k) vs EU MDR: Which Route a Home IPL Device Needs

The FDA 510(k) route and the EU MDR route are often compared as if they were two doors into the same room. They are not. They ask different questions, and they place the compliance responsibility in different hands.

That difference decides your budget more than the technical requirements do.

The two questions each regime asks

The 510(k) process asks one question: is this device substantially equivalent to a legally marketed predicate device. You answer it with a comparison, supported by testing. If the answer holds, you receive a clearance number.

MDR asks a different question first: is this a medical device at all. If it is, a second question follows about which class, and a third about whether a notified body must assess your quality system and clinical evidence.

One is a comparison exercise. The other is an assessment of you as a manufacturer.

Cost and calendar, side by side

On the US side, the direct costs are the testing needed to support equivalence and the submission itself. The calendar is driven by how close your device sits to a predicate. A near-identical device moves quickly. A device that needs new performance data does not.

On the EU side, the costs sit in the quality system and the clinical evaluation, and the calendar sits in the notified body queue. That queue is not something a good consultant can shortcut. It is capacity.

The asymmetry that surprises brands: the US route can look cheaper and faster right up to the moment the EU route becomes mandatory, at which point the work does not reuse much of the US file. The two dossiers share test data, not structure.

If you want the EU side in detail, including the EUDAMED lookup and the Annex XVI transition, that is covered separately. This piece stays on the comparison.

Who the legal manufacturer is, and why it decides everything

This is the part that costs the most money when it is discovered late.

Under MDR, the certificate names a legal manufacturer. That entity carries the obligations. If you are a brand contracting a factory, you are usually not that entity, and the factory may not be either, because the party that put the device on the market under its own name is.

Under 510(k), the clearance is held by a specification developer. It is a named party too, and it can be different from the factory that builds the device.

So a supplier switch is not just a production change. It is a question about which named party survives the move. We walk through the four costs of that in the switching piece, and the identity question is the one that most often turns a three-month plan into a year.

The transition trap for newer products

The EU transition provisions have a date condition that catches brands who assume a grace period applies to them.

Devices that were lawfully placed on the market before a cut-off can continue under transitional rules, provided they meet the conditions attached. A model launched after that date, or one that has been significantly modified, is not covered and needs a valid certificate from the start.

The practical consequence: a device you launched recently may have no transitional shelter, even if an older model from the same factory does. Whether that matters depends on how the device is classified, which is why this question belongs to a regulatory advisor rather than to a marketing team.

When 510(k) is not enough, and when MDR is unavoidable

510(k) is not enough when the device cannot be shown equivalent without new clinical data, which pushes the submission toward a different pathway with its own evidence burden.

MDR becomes unavoidable when the device is classified as a medical device and no transition applies. At that point the notified body question is not optional, and the quality system becomes the subject rather than the device alone.

There is a third case that gets missed: a device that is consumer electronics in one market and a medical device in another because the claims differ. That is why the labelling decision is a compliance decision and not a copywriting one.

A decision table by market and volume

Situation	US	EU
New brand, first product, claims limited to hair removal	510(k) usually required; budget testing early	Classify first; consumer-electronics route may apply
1,000–5,000 units a month, established product	Clearance already held; keep it current	Quality system becomes the audit target
Model launched after the EU cut-off, modified since	May need new comparison work	No transition; certificate needed
Switching to a new factory	Determine who the specification developer is	Determine who the legal manufacturer becomes

The table is a starting point, not advice. The classification column is the one that needs a professional opinion written down, not assumed.

What this means for a sourcing decision

Ask every candidate supplier two questions before discussing price.

Who is the legal manufacturer on your certificate, and who is the specification developer on your clearance. If the answer is “the factory” for one and “a partner” for the other, you have found the real structure of the deal.

What happens to those names if we change factories. A supplier who can answer this has been through it. A supplier who cannot has always been the only factory in the story.

We collect both documents among the seven we ask for before a deposit, and the validation schedule by volume shows where each route starts to bind as order size grows. For Canada there is a separate licence question, covered in its own piece.